American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium

Data Demonstrates Once Weekly Drug as Potential Solution for Patients with Type 2 Diabetes, Obesity and Fatty Liver Disease SAN DIEGO, June 26, 2023 /PRNewswire/ — Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable…

Click here to view original post